Associations between Antidiabetic Drug Classes and Aortic Aneurysm Risk in Patients with Type 2 Diabetes: A Nationwide Cohort Study.
Abstract
Objective
Aortic aneurysm (AA) is a potentially life threatening condition that often remains asymptomatic for prolonged periods. Although type 2 diabetes mellitus (T2DM) increases cardiovascular risk, epidemiological studies have paradoxically reported a lower incidence of AA in patients with T2DM. Antidiabetic therapies may contribute to this inverse association, but class specific effects remain unclear. This study evaluated associations between antidiabetic drug classes and incident AA.
Methods
This was a nationwide, population based, retrospective cohort study of adults with T2DM in Taiwan's National Health Insurance Research Database between 2009 and 2022. Associations between antidiabetic drug classes and incident AA were evaluated using Cox proportional hazards models with time varying medication exposure, adjusted for demographic characteristics, diabetes severity, comorbidities, tobacco related diagnoses, and concomitant medications. Subgroup and sensitivity analyses were considered exploratory.
Results
Among 3 295 564 adults with T2DM (mean age 60.0 years; 52.8% men) followed for 8.5 ± 4.7 years, 45.5% received at least three antidiabetic drug classes. In multivariable time varying Cox models, metformin (adjusted hazard ratio [aHR] 0.78, 95% confidence interval [CI] 0.75 - 0.82), thiazolidinediones (aHR 0.71, 95% CI 0.65 - 0.77), sulfonylureas/meglitinides (aHR 0.82, 95% CI 0.78 - 0.85), and α-glucosidase inhibitors (aHR 0.83, 95% CI 0.77 - 0.89) were associated with lower AA risk. DPP-4 inhibitors (aHR 0.95, 95% CI 0.90 - 1.00), sodium-glucose cotransporter 2 (SGLT2) inhibitors (aHR 0.90, 95% CI 0.81 - 1.00), and glucagon like peptide 1 receptor agonists (GLP-1RAs) (aHR 0.69, 95% CI 0.50 - 0.95) also showed inverse associations, whereas insulin use was associated with higher AA risk (aHR 1.14, 95% CI 1.08 - 1.20). The inverse associations of conventional oral antidiabetic agents remained robust across sensitivity analyses. In contrast, the inverse associations for DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1RAs were attenuated and no longer statistically significant in patients with an index date from 2011 onward.
Conclusion
In this nationwide T2DM cohort, conventional oral antidiabetic agents were consistently associated with a lower observed AA risk. Although newer glucose lowering therapies showed similar inverse associations, these findings were less robust and warrant cautious interpretation and prospective confirmation.